Back to Screener

Healthcare

eXoZymes, Inc.(EXOZ)

Live Price

Offline

$8.03

+8.51% today

1Y Change

-18.72%

Window

Jun 30, 2025 โ†’ Jun 26, 2026

Market Cap
$90.00M
Revenue Growth
0.0%
EPS Growth
-51.4%
Dividend Yield
0.0%

Coverage: 249 bars ยท Jun 30, 2025 โ†’ Jun 26, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

eXoZymes, Inc. (EXOZ) is a Healthcare stock with a market cap of $90.00M and listed on NASDAQ. The stock last traded around $8.03 and down 18.7% across the available one-year price window (Jun 30, 2025 โ†’ Jun 26, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -51.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -51.4%, free cash flow +25.1% with operating margin 0.0% and ROIC -203.1%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines EXOZ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

EXOZ vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

Relative Read

EXOZ trails SPY

EXOZ is 36.71 pts behind over the shared 1Y window.

EXOZ had 52.50 pts deeper max drawdown than SPY.

EXOZ beat SPY in 1 of 2 calendar years shown and trailed in 1.

EXOZ

-18.72%

Normalized return

SPY

+17.99%

S&P 500

Excess Return

-36.71 pts

Relative to SPY

EXOZ Max Drawdown

-61.64%

Trailing 1Y

SPY Max Drawdown

-9.13%

Trailing 1Y

EXOZSPY

Calendar-Year Returns

Uses the longest available daily history for EXOZ and SPY.

YearEXOZSPYExcessLeader
2026-26.93%+6.71%-33.64 ptsSPY
2025+12.60%+11.19%+1.41 ptsEXOZ

Unable to load analyst forecasts.

Timed out loading forecasts for EXOZ

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.